KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Hims & Hers Health (HIMS) EBITDA Margin (2020 - 2025)

Hims & Hers Health (HIMS) has disclosed EBITDA Margin for 6 consecutive years, with 3.56% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 174.0% to 3.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.58% through Dec 2025, down 294.0% year-over-year, with the annual reading at 5.58% for FY2025, 294.0% down from the prior year.
  • EBITDA Margin hit 3.56% in Q4 2025 for Hims & Hers Health, up from 2.65% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18.92% in Q3 2024 to a low of 98.38% in Q1 2021.
  • Historically, EBITDA Margin has averaged 9.07% across 5 years, with a median of 3.4% in 2023.
  • Biggest five-year swings in EBITDA Margin: tumbled -7817bps in 2021 and later soared 8215bps in 2022.
  • Year by year, EBITDA Margin stood at 36.89% in 2021, then skyrocketed by 83bps to 6.41% in 2022, then surged by 108bps to 0.51% in 2023, then soared by 941bps to 5.29% in 2024, then crashed by -33bps to 3.56% in 2025.
  • Business Quant data shows EBITDA Margin for HIMS at 3.56% in Q4 2025, 2.65% in Q3 2025, and 7.98% in Q2 2025.